FDA mandates vision-loss warning on weight-loss pens after rare eye disease signal

The US FDA is requiring a new warning on weight-loss injection pens (GLP-1 drugs) after identifying a possible increased risk of a rare eye disease. The regulatory action follows a safety signal, though causality and magnitude remain under investigation. This could affect prescribing patterns and manufacturer liability.

AI disclosure: Model-written summary of the source, not a verified fact. Check the sources. How Mosaic works